

# Yue Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/286303/publications.pdf>

Version: 2024-02-01

7  
papers

215  
citations

1684188

5  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

247  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non-small cell lung cancer cells. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	1.1	7
2	The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 429-445.	6.1	5
3	LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity. <i>Oncogene</i> , 2020, 39, 2290-2304.	5.9	26
4	The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt-PCAF pathway in promotion of esophageal squamous cell carcinoma growth. <i>Nucleic Acids Research</i> , 2020, 48, 4858-4876.	14.5	31
5	Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 530-538.	6.1	17
6	Aspirin targets P4HA2 through inhibiting NF- $\kappa$ B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 45, 168-180.	6.1	79
7	Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 26.	17.0	50